UA-45667900-1

Thursday, 9 May 2013

Praise the Lord and pass the Statins - Part 1

If you are not a native English speaker, you may not have heard the praise “praise the Lord and pass the ammunition”.  It originates from a song written after the Japanese attack on Pearl Harbour in 1942.  A warship’s chaplain puts down his bible and mans a gun firing back at the incoming enemy planes saying, "Praise the Lord and pass the ammunition".

According to Wikipedia, the chaplain was Howell Forgy, was aboard the USS New Orleans.

To hear an original recording click here.

In our case the enemy is neuroinflammation, rather than the Japanese.

 
Deborah Fein and Martha Herbert

There are some very good researchers in the field of Autism and these two ladies are on my list of the best.  It looks like this paper was mainly the work of Ms Fein’s colleagues at the University of Connecticut: - Can children with autism recover? If so, How?

The paper is very readable and not science-heavy at all.

One of the explanations put forward for the rare event of recovery, was the possible reduction in neuroinflammation.  This very much fits in with the conclusions so far on my blog;  reduce neuroinflammation and in particular in the cerebellum.

Now we have a brief time-out to introduce you to our new friends, the Statins.






Source: W. Gibson Wood, Ph.D.  Department of Pharmacology, University of Minnesota


Statins

Statins are a class of drug used to lower cholesterol levels by inhibiting an enzyme which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been associated with cardiovascular diseases and statins are therefore used in the prevention of these diseases. Research has found that statins are most effective for treating cardiovascular disease (CVD), with questionable benefit in those without previous CVD, but with elevated cholesterol levels.

Statins act by competitively inhibiting HMG-CoA reductase, the first committed enzyme of the HMG-CoA reductase pathway. Because statins are similar to HMG-CoA on a molecular level, they take the place of HMG-CoA in the enzyme and reduce the rate by which it is able to produce mevalonate, the next molecule in the cascade that eventually produces cholesterol, as well as a number of other compounds. This ultimately reduces cholesterol via several mechanisms.

1.     Inhibiting cholesterol synthesis

By inhibiting HMG-CoA reductase, statins block the pathway for synthesizing cholesterol in the liver. This is significant because most circulating cholesterol comes from internal manufacture rather than the diet. When the liver can no longer produce cholesterol, levels of cholesterol in the blood will fall. Cholesterol synthesis appears to occur mostly at night so statins with short half-lives are usually taken at night to maximize their effect. Studies have shown greater LDL and total cholesterol reductions in the short-acting simvastatin taken at night rather than the morning, but have shown no difference in the long-acting atorvastatin.

2.     Increasing LDL uptake
 
3.    Other effects

Statins exhibit action beyond lipid-lowering activity in the prevention of atherosclerosis. Researchers hypothesize that statins prevent cardiovascular disease via four proposed mechanisms (all subjects of a large body of biomedical research)
  1. Improve endothelial function
  2. Modulate inflammatory responses
  3. Maintain plaque stability
  4. Prevent thrombus formation
Statins may even benefit those without high cholesterol. In 2008, the JUPITER study showed fewer strokes, heart attacks, and surgeries even for patients who had no history of high cholesterol or heart disease, but only elevated C-reactive protein levels

 

*****************   Now back to today’s post  *******************

 
Neuroinflammation in the Cerebellum

How hard can it be to find a therapy for neuroinflammation in the cerebellum?  Thanks to Google Scholar, the answer is a few clicks away.

First of all we need to find what other diseases affect the cerebellum or cause inflammation there.  I settled on two completely different cases to investigate:-

1.    Cerebral Malaria 

2.    Traumatic Brain Injury (TBI)

 
Cerebral Malaria (CM) 

First let’s look at what happens in cases of cerebral malaria:-

i) Cognitive sequelae
ii) Speech and language impairment
iii) Epilepsy
iv) Behavior and neuro-psychiatric disorders

Now remember we are looking at malaria, not autism; but this list could just a well be a summary of the effects of autism.


An emerging area of research is the applications of statins to reduce the neuroinflammation caused by this type of malaria.

Here the secondary action of the statin is important; cholesterol reduction is not relevant.  Here are some highlights:-

·         Cognitive impairment in animals rescued from CM by antiplasmodial drug treatment is abrogated by adjuvant lovastatin administration

·         Lovastatin treatment increases functional capillary density and decreases leukocyte-endothelial interactions

·         Lovastatin protects against blood-brain barrier disruption

·         Lovastatin treatment reduces cytokine levels

·         Lovastatin treatment decreases ROS production


 
Traumatic Brain Injury (TBI)

It is self-evident that a traumatic brain injury, like a car crash, will lead to neuroinflammation.   The search is on here to find optimal ways to treat this inflammation and achieve an optimal outcome.
 
Here is one paper: - Statins in Traumatic Brain Injury
  
"The use of statins remains a novel therapeutic strategy for TBI. There is robust preclinical data demonstrating the efficacy of statins in acute brain injury models that recapitulate the heterogeneous pathology of clinical TBI. Animal studies have defined mechanisms by which statins may improve outcomes after TBI and should guide statin choice and dosing paradigm for clinical translation."



A more general paper is:- Statins and Brain Dysfunction


This should be an interesting paper, but only the abstract is free:-  How do statins control neuroinflammation?


Conclusion

Statins are among the world’s top selling drugs.  With so many people using them, there are of course reported side effects; but as drugs go, the side effects look pretty minimal.  Those at high risk of heart disease, such as those with Type 1 diabetes, are routinely prescribed statins even from a relatively early age.

It has been claimed that autistic people are already at higher risk of heart disease, due to their low level of good cholesterol (HDL) and sometimes higher level of bad cholesterol (LDL). The research is not 100% consistent; but it is very easy to go and check your child's cholesterol.  Holding him still while they draw the blood is another story ....

So it would appear there is one and maybe two very good reasons for autistic people to take statins.


Click below to see Part 2, to decide which statin to choose (there are many).
 

Wednesday, 8 May 2013

Neurogenesis & Neuroplasticity


Today we have two new N- words and we finally get to the bottom of what autism is and what it is not.   There is nothing revolutionary here, it can all be found in the research and indeed most of it can be found in just one book, but then who would read my blog?
We will start with the bad news and finish with the good news.

Neurogenesis
Neurogenesis sounds like a good thing; it is the birth of neurons in the brain.  This is substantially completed in the pre-natal period, but it can continue in certain parts of the brain throughout life.  After a head injury, or trauma, neurogenesis can take place.

In the case of autism the potential benefit exists, but seems likely to be minimal.
Many studies have already established the pattern of deformities in the autistic brain.  One researcher in particular, Eric Courchesne, seems to have chosen to make this his life’s work.  He has carried out repeated studies over many years focused on examination of brain growth, and overgrowth, in autism using post-mortem brains and later MRI (magnetic resonance imaging).
His findings are unequivocal, and in line with those of his peers.  In his autistic subjects, the brain grows much faster in the first couple of years than typical subjects and then the process slows right down and in later life the autistic brain starts to shrink.  His and other studies show that in later life the brain does seem to try to compensate for its defective development; this is seen as ineffective (but how can anyone possibly know?).

He finds a wide pattern of abnormalities, including the expected presence of a reduced number of Purkinje cells.  He goes on to argue that his evidence shows that this damage was done in the pre-natal period, so he will not be popular with the vaccine damage theorists.

“Thus, given the resulting tight bond between the olivary neurons and the Purkinje cells after this time, loss or damage to the cerebellar Purkinje cells results in an obligatory retrograde loss of olivary neurons. Since, in the autistic brain, the number of the olivary neurons is preserved, it is likely that whatever event resulted in the reduction of the Purkinje cells in these cases has to have occurred before this tight bond has been  established, and thus before 28–30 weeks gestation.”
 
“In addition, microscopic observations of enlarged cells in some brain regions in autistic children and small pale cells that are reduced in number in these same areas in adults strongly indicate changes with age. Clinically and pathologically, this process does not appear to a degenerative one and may reflect the brain’s attempt to compensate for its atypical circuitry over time.”

“This early cessation of growth results in a 2–4 year old autistic brain size that is not different from a normal adolescent or adult in the majority of cases. Thus, at the age of typical clinical diagnosis of the disorder (i.e. 3–4 years), the period of pathological growth and arrest has likely already passed, leaving clinicians and researchers with an outcome, rather than process, of pathology for study and treatment intervention.”

Here are three of Eric’s studies, which include graphs showing autistic brain development vs. the control group at various ages throughout life.


Neuroplasticity
If neurogenesis was the bad news then neuroplasticity is certainly the good news. I think that Eric needs to read up on this subject and perk himself up.  It seems even a deformed brain can do some pretty clever stuff.

Neuroplasticity, also known as brain plasticity, refers to changes in neural pathways and synapses which are due to changes in behavior, environment and neural processes, as well as changes resulting from bodily injury.  Neuroplasticity has replaced the formerly-held position that the brain is a physiologically static organ, and explores how - and in which ways - the brain changes throughout life.
In the field of neuroplasticity we have some pioneering work from  Michael Merzenich is a neuroscientist. He has made some of "the most ambitious claims for the field - that brain exercises may be as useful as drugs to treat diseases as severe as schizophrenia - that plasticity exists from cradle to the grave, and that radical improvements in cognitive functioning - how we learn, think, perceive, and remember are possible even in the elderly."  Merzenich’s work was affected by a crucial discovery made by Hubel and Wiesel in their work with kittens. The experiment involved sewing one eye shut and recording the cortical brain maps. Hubel and Wiesel saw that the portion of the kitten’s brain associated with the shut eye was not idle, as expected. Instead, it processed visual information from the open eye. It was"… as though the brain didn’t want to waste any ‘cortical real estate’ and had found a way to rewire itself.
Merzenich created a plasticity-based computer aided learning programme called FastForWord, which  offers seven brain exercises to help with the language and learning deficits of dyslexia.

ABA and neuroplasticity.  Then of course, I started thinking about Monty’s  6 years of ABA and endless hours on his computer based learning programmes.  This of course is the link between neuroscience and ABA - the fuzzy science of neuroplasticity; otherwise known as making the most of what you’ve got. 
 
Conclusion
We have established that autistic behaviours are likely caused by stress and inflammation in the cerebellum, and in particular in the region of the Purkinje Cell Layer (PCL).

We have seen that in classic autism this stress and inflammation is associated with physical brain growth abnormalities that occurred in the pre-natal and early post natal period.  The oxidative stress and inflammation is ongoing throughout adulthood.
We have seen that stress and inflammation in the cerebellum can be caused by entirely different causes, that take effect later in life, such as Tuberous Sclerosis Complex (TSC).  There is another truly horrible one called Childhood Disintegrative Disorder (CDD).

With the availability of noninvasive MRI scans, it would be interesting and highly possible to ascertain the level of brain deformity in milder cases of autism and Asperger’s syndrome. 
Given that by the time autistic behaviors are exhibited, the damage to the brain  has already run its course, our main ally would seem to be neuroplasticity and of course to halt the ongoing oxidative stress and inflammation.

In addition, we need to consider countering the apparent ion-channel disfunction, and maybe give the damaged hippocampus a lesson or two about hormone production.

 

 

 

Tuesday, 7 May 2013

Pep up those Purkinje cells

In the previous post we established that both oxidative stress and neuroinflammation can be measured.  We learned from the clever people at Johns Hopkins that the site of the greatest inflammation is in the  cerebelleum; as they put it:-

Based on our observations, selective processes of neuronal degeneration and neuroglial activation appear to occur predominantly in the Purkinje cell layer (PCL) and granular cell layer (GCL) areas of the cerebellum in autistic subjects.

Now, you may recall that I recommended an excellent book called "Autism: Oxidative Stress, Inflammation and Immune Abnormalities".  The book is from 2010, and since then the authors have been busy.  In 2012 they published a study called:   Brain Region-Specific Glutathione Redox Imbalance in Autism
This study tells us which parts of the brain are most affected by oxidative stress.  The abnormal level of GSH redox (the marker for oxidative stress) was highest in the cerebellum and in the temporal cortex.
This is good to hear, since I have assumed that oxidative stress and neuroinflammation are essentially part of the same process and that what halts one, will likely halt the other.
 

Purkinje Cells
Purkinje cells are a class of GABAergic (controlled by the neurotransmitter GABA) located in the cerebellum.
Purkinje cells are some of the largest neurons in the human brain, perhaps this makes them target of stress and inflammation.
Purkinje cells send inhibitory projections to the deep cerebellar nuclei, and constitute the sole output of all motor coordination (and maybe more?) from the cerebellum.

In humans, Purkinje cells are affected in a variety of diseases ranging from toxic exposure (alcohol, lithium), to autoimmune diseases and to genetic mutations (spinocerebellar ataxias, Unverricht-Lundborg disease and autism) and neurodegenerative diseases that are not thought to have a known genetic basis (cerebellar type of multiple system atrophy, sporadic ataxias).

Purkinje Damage in Autism
It has been shown that there is a 35 to 50% reduction in the number of Purkinje cells in the autistic cerebellum when compared with a normal cerebellum.  (this comes from a paper on glutamate neuro-transmitter abnormalities)

Here is an excellent and  very readable study all about Purkinje damage in autism, from 10 years ago:-
 Purkinje cell vulnerability and autism: a possible etiological connection

It is proposed that the cell death in the Purkinje cell layer produces the autistic-like behaviours.

Functions of the and temporal lobe and cerebellum
(where the oxidative stress was measured to be highest)

The temporal lobe seem very much related to the problematic areas of autistim, namely:-
·         Processing sensory input

·         Language comprehension
It also contains the hippocampus.  The hippocampus has made an earlier appearance on this blog since one of its main functions is the realease of hormones including TRH (thyrotropin releasing hormone) CRH (Corticotropin releasing hormone) GHRH (growth hormone releasing hormone).  Disfunction of the hippocampus is known to occur in epilepsy (often comorbid with autism).
If you want to read all about the temporal lobe, try this : Anatomy of the temporal lobe.

The cerebellum is commonly associated with motor control function, but it may have a role in cognitive function, such as language.  Damage to the cerebellum is known to causes disorders in fine movement (sloppy handwriting in autism?)
So it would appear at first glance that inflammation in the temporal lobe and cerebellum could indeed account for many autistic-like behaviors.  

 
Pep up those Purkinje cells  -  Indirect or direct action?
As is often the case, there is the direct approach and the indirect approach.  I usually favour the subtle indirect approach; this would be to work on reducing the oxidation and inflammation. 

There may also a direct approach, using a drug developed as an anti-fungal agent, that turned out to be a potent immunosuppressant.    It prevents activation of T cells and B cells by inhibiting their response to interleukin (IL-2). 

Since nothing in neuroscience is clear cut, there is of course a far more complicated alternative explanation of what is going on.  It could be a genetic disorder that is causing the failure in the Purkinje cells.  Take a look:-

Tuberous sclerosis complex (TSC) is a dominant tumour suppressor disorder caused by mutations in either TSC1 or TSC2. TSC causes substantial neuropathology, often leading to autism spectrum disorders (ASDs) in up to 60% of patients. The anatomic and neurophysiologic links between these two disorders are not well understood…. These studies provide compelling evidence that Purkinje cell loss and/or dysfunction may be an important link between TSC and ASD as well as a general anatomic phenomenon that contributes to the ASD phenotype.


The good news is that TSC already has a viable therapy (in mice at least, and in clinical trials), with a drug called rapamycin/sirolimus.  If you look on the web, you will find people experimenting with it.
There have been several studies using mutant mice. 

Autism in mice

In a study of sirolimus as a treatment for TSC, researchers observed a major improvement regarding effects related to autism. The researchers discovered sirolimus regulates one of the same proteins the TSC gene does, but in different parts of the body. They decided to treat mice three to six months old (adulthood in mice lifespans); this increased the autistic mice's intellect to about that of normal mice in as little as three days.

Here are two studies:- 


Before heading down to the pharmacy to ask about Rapamycin, click on this to see a warning or two.  Also TSC is a genetic condition that usually leads to autism.  This does not mean that if you have autism you also have TSC.  It does mean that better understanding TSC may help to better undertand autism.


It looks like the indirect approach is best again.  Just keep taking the NAC !!

 

 

Sunday, 5 May 2013

Stress, Neuroinflammation and Magnolia before bed

In earlier posts we learned about two kinds of stress:-
  • Oxidative stress is a biological stress that is measurable (GSH redox) and has been shown to be present in most autistic people.
  • Psychological stress is a feeling we experience in difficult situations and is measurable by sampling the level of the hormone cortisol in saliva.
It would appear that both types of stress are interrelated.
We have already established that oxidative stress in autism can be successfully be treated with NAC.  NAC acts both as an anti-oxidant in its own right and as a precursor chemical to form GSH, the body’s own antioxidant.  NAC is cheap and widely available.
The scientific literature regarding autism includes many references to inflammation of the brain, or neuroinflammation. It turns out that this inflammation is also measurable.  When samples of cerebrospinal fluid (CSF) are taken, elevated levels of chemicals called cytokines are found.  Certain cytokines are markers for neuroinflammation, such as TGF-ß1 and MCP-1.
In studies at Johns Hopkins, a leading teaching hospital in the US, they have tested all their autistic research subjects for neuroinflammation and they all tested positive.  It also appears that this is the result of on-going damage to the brain, not residual damage from the pre-natal or early post natal period.  Such damage was exhibited in autistic subjects of all ages.  These researchers were also able to locate the part of the brain most affected by neuroinflammation.
“Our study showed the cerebellum exhibited the most prominent neuroglial responses. The marked neuroglial activity in the cerebellum is consistent with previous observations that the cerebellum is a major focus of pathological abnormalities in microscopic and neuroimaging studies of patients with autism. Based on our observations, selective processes of neuronal degeneration and neuroglial activation appear to occur predominantly in the Purkinje cell layer (PCL) and granular cell layer (GCL) areas of the cerebellum in autistic subjects. These findings are consistent with an active and on-going postnatal process of neurodegeneration and neuroinflammation.”
There are numerous other researchers who concur with these findings; the problem is that they do not take the logical next step of finding how to reduce this inflammation.  Indeed John’s Hopkins go as far as to tell us
“At present, THERE IS NO indication for using anti-inflammatory medications in patients with autism. Immunomodulatory or anti-inflammatory medications such as steroids (e.g. prednisone or methylprednisolone), immunosupressants (e.g. Azathioprine, methotrexate, cyclophosphamide) or modulators of immune reactions (e.g. intravenous immunoglobulins, IVIG) WOULD NOT HAVE a significant effect on neuroglial activation because these drugs work mostly on adaptive immunity by reducing the production of immunoglobulins, decreasing the production of T cells and limiting the infiltration of inflammatory cells into areas of tissue injury. Our study demonstrated NO EVIDENCE at all for these types of immune reactions. There are on-going experimental studies to examine the effect of drugs that limit the activation of microglia and astrocytes, but their use in humans must await further evidence of their efficacy and safety” 
Here the researchers were experimenting with various chemical including NAC as an antioxidant.
“Activation of microglia has been implicated in the pathogenesis of a variety of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Creutzfeld-Jacob disease, HIV-associated dementia (HAD), stroke, and multiple sclerosis (MS) . It has been found that activated microglia accumulate at sites of injury or plaques in neurodegenerative CNS. Although activated microglia scavenge dead cells from the CNS and secrete different neurotropic factors for neuronal survival, it is believed that severe activation causes inflammatory responses leading to neuronal death and brain injury. During activation, microglia secretes various neurotoxic molecules and express different proteins and surface markers.
Although microglia populate only 2 to 3% of total brain cells in a healthy human being, the number increases up to 12 to 15% during different neurodegenerative diseases. Microglial activation is always associated with neuronal inflammation and ultimately neuronal apoptosis. Although microglial activation may not be always bad as it has an important repairing function as well, once microglia become activated in neurodegenerating microenvironment, it always goes beyond control and eventually detrimental effects override beneficial effects. Therefore, microglial activation is a hallmark of different neurodegenerative diseases and understanding underlying mechanisms for microglial activation is an important area of study. “ 
Another piece of research that looked at activated microglia in a neurological condition (this time Alzheimer’s disease) also used NAC as an antioxidant and anti-inflammatory agent.

Now, to better understand the terminology and the science, a little bit of biology would be useful.  If you wish to skip this part, you can go forward a few pages to the part where I look at practical steps that seem likely to reduce neuroinflammation.
 Here are the key words we need to understand:- 
  • Neurons
  • Neurotransmitters
  • Glial cells
  • Microglia
  • Astrocytes or astroglia
  • Cytokenes

Thanks to Wikipedia I have presented a summary.
 1.  Neurons
A neuron is a cell that processes and transmits information through electrical and chemical signals. A chemical signal occurs via a synapse a specialized connection with other cells. Neurons connect to each other to form neural networks. Neurons are the core components of the CNS (Central Nervous System), which includes the brain and spinal cord. A number of specialized types of neurons exist: sensory neurons respond to touch, sound, light and numerous other stimuli affecting cells of the sensory organs that then send signals to the spinal cord and brain. Motor neurons receive signals from the brain and spinal cord, cause muscle contractions, and affect glansa. Interneurons connect neurons to other neurons within the same region of the brain or spinal cord.

 

2.  Neurotransmitters - interaction between neurons
A neuron affects other neurons by releasing a neurotransmitter that binds to chemical receptors. The effect upon the postsynaptic neuron is determined not by the presynaptic neuron or by the neurotransmitter, but by the type of receptor that is activated. A neurotransmitter can be thought of as a key, and a receptor as a lock: the same type of key can here be used to open many different types of locks. Receptors can be classified broadly as excitatory (causing an increase in firing rate), inhibitory (causing a decrease in firing rate), or modulatory (causing long-lasting effects not directly related to firing rate).
The two most common neurotransmitters in the brain, and GABA, have actions that are largely consistent. Glutamate acts on several different types of receptors, and have effects that are excitatory at ionotropic receptors and a modulatory effect at metabotropic receptors. Similarly GABA acts on several different types of receptors, but all of them have effects (in adult animals, at least) that are inhibitory. Because of this consistency, it is common for neuroscientists to simplify the terminology by referring to cells that release glutamate as "excitatory neurons," and cells that release GABA as "inhibitory neurons." Since over 90% of the neurons in the brain release either glutamate or GABA, these labels encompass the great majority of neurons.

GABA is very important in autism and we will return to it in greater depth when we will look at the three types of GABA receptors.

3.   Glial cells
Glial cells are non-neuronal cells that maintain homeostasis and provide support and protection for neurons in the brain, and for neurons in other parts of the nervous system such as in the autonomic nervous system.
Four main functions of glial cells have been identified:
  1. To surround neurons and hold them in place,
  2. To supply nutrients and oxygen to neurons,
  3. To insulate one neuron from another,
  4. To destroy pathogens and remove dead neurons.
Glial cells do modulate neurotransmission, although the mechanisms are not yet well understood.
 
Functions

Some glial cells function primarily as the physical support for neurons. Others regulate the internal environment of the brain, especially the fluid surrounding neurons and their synapses, and nutrify neurons. During early embryogenesis glial cells direct the migration of neurons and produce molecules that modify the growth of axons and dendrites. Recent research indicates that glial cells of the hippocampus and cerebellum participate in synaptic transmission, regulate the clearance of neurotransmitters from the synaptic cleft, and release gliotransmitters such as ATP, which modulate synaptic function.
Glial cells were not believed to have chemical synapses or to release transmitters. They were considered to be the passive bystanders of neural transmission. However, recent studies have shown this to be untrue. For example, astrocytes are crucial in clearance of neurotransmitters from within the synaptic cleft, which provides distinction between arrivals of action potentials and prevents toxic build-up of certain neurotransmitters such as glutamate (excitotoxicity). It is also thought that glia play a role in many neurological diseases, including Alzheimer’s disease. Furthermore, at least in vitro, astrocytes can release gliotransmitter glutamate in response to certain stimulation.
Glia have a role in the regulation of repair of neurons after injury. In the CNA (Central Nervous System), glia suppress repair. Glial cells known as astrocytes enlarge and proliferate to form a scar and produce inhibitory molecules that inhibit regrowth of a damaged or severed axon. In the PNS (Peripheral Nervous System), glial cells known as Schwann cells promote repair. After axonal injury, Schwann cells regress to an earlier developmental state to encourage regrowth of the axon. This difference between PNS and PNS raises hopes for the regeneration of nervous tissue in the CNS. For example a spinal cord may be able to be repaired following injury or severance.

4.  Microglia
Microglia are a type of glial cell that are the resident macrophages of the brain and spinal cord, and thus act as the first and main form of active immune defense in the CNS. Macrophages are highly specialized in removal of dying or dead cells and cellular debris. This role is important in chronic inflammation, as the early stages of inflammation are dominated by neutrophil granulocytes, which are ingested by macrophages if they come of age.
Microglia constitute 20% of the total glial cell population within the brain.] Microglia (and astrocytes) are distributed in large non-overlapping regions throughout the brain and spinal cord.  Microglia are constantly scavenging the CNS for plaques, damaged neurons and infectious agents. The brain and spinal cord are considered "immune privileged" organs in that they are separated from the rest of the body by a series of endothelial cells known as the blood brain barrier (BBB), which prevents most infections from reaching the vulnerable nervous tissue. In the case where infectious agents are directly introduced to the brain or cross the blood–brain barrier, microglial cells must react quickly to decrease inflammation and destroy the infectious agents before they damage the sensitive neural tissue. Due to the unavailability of antibodies from the rest of the body (few antibodies are small enough to cross the blood brain barrier), microglia must be able to recognize foreign bodies, swallow them, and act as antigen presenting cells activating T-cells. Since this process must be done quickly to prevent potentially fatal damage, microglia are extremely sensitive to even small pathological changes in the CNS. They achieve this sensitivity in part by having unique potassium channels that respond to even small changes in extracellular potassium.
5.  Astrocytes or astroglia,
Astrocytes or astroglia are characteristic star-shaped glial cells in the brain and spinal cord. They are the most abundant cell of the human brain. They perform many functions, including biochemical support of endothelial cells that form the blood-brain barrier, provision of nutrients to the nervous tissue, maintenance of extracellular ion balance, and a role in the repair and scarring process of the brain and spinal cord following traumatic injuries.
Research since the mid-1990s has shown that astrocytes propagate intercellular Ca2+- waves over long distances in response to stimulation, and, similar to neurons, release transmitters (called gliotransmitters) in a Ca2+-dependent manner. Data suggest that astrocytes also signal to neurons through Ca2+-dependent release of glutamate. Such discoveries have made astrocytes an important area of research within the field of neuroscience..
Previously in medical science, the neuronal network was considered the only important one, and astrocytes were looked upon as gap fillers. More recently, the function of astrocytes has been reconsidered, and are now thought to play a number of active roles in the brain, including the secretion or absorption of neural transmitters and maintenance of the blood–brain barrier.  Following on this idea the concept of a "tripartite synapse" has been proposed, referring to the tight relationship occurring at synapses among a presynaptic element, a postsynaptic element and a glial element.
  • Structural: They are involved in the physical structuring of the brain. Astrocytes get their name because they are "star-shaped". They are the most abundant glial cells in the brain that are closely associated with neuronal synapses. They regulate the transmission of electrical impulses within the brain.
  • Glycogen fuel reserve buffer: Astrocytes contain glycogen and are capable of glycogenesis. The astrocytes next to neurons in the frontal cortex and hippocampus store and release glycogen. Thus, Astrocytes can fuel neurons with glucose during periods of high rate of glucose consumption and glucose shortage. Recent research suggests there may be a connection between this activity and exercise.
  • Metabolic support: They provide neurons with nutrients such as lactate.
  •  Blood-brain barrier: The astrocyte end-feet encircling endothelial cells were thought to aid in the maintenance of the blood–brain barrier, but recent research indicates that they do not play a substantial role; instead, it is the tight junctions and basal lamina of the cerebral endothelial cells that play the most substantial role in maintaining the barrier. However, it has recently been shown that astrocyte activity is linked to blood flow in the brain, and that this is what is actually being measured in fMRI.
  • Transmitter uptake and release: Astrocytes express plasma membrane transporters such as glutamate transporters for several neurotransmitters, including glutamate, ATP, and GABA. More recently, astrocytes were shown to release glutamate or ATP in a vesicular, Ca2+-dependent manner.
  •  Regulation of ion concentration in the extracellular space Astrocytes express potassium channels at a high density. When neurons are active, they release potassium, increasing the local extracellular concentration. Because astrocytes are highly permeable to potassium, they rapidly clear the excess accumulation in the extracellular space. If this function is interfered with, the extracellular concentration of potassium will rise, leading to neuronal depolarization by the Goldman equation. Abnormal accumulation of extracellular potassium is well known to result in epileptic neuronal activity.
  • Vasomodulation: Astrocytes may serve as intermediaries in neuronal regulation of blood flow.
  • Nervous system repair: Upon injury to nerve cells within the central nervous system, astrocytes fill up the space to form a glial scar, repairing the area and replacing the CNS cells that cannot regenerate.
  • Long-term potentiation: Scientists continue to argue back and forth as to whether or not astrocytes integrate learning and memory in the hippocampus. It is known that glial cells are included in neuronal synapses, but many of the LTP studies are performed on slices, so scientists disagree on whether or not astrocytes have a direct role of modulating synaptic plasticity.
 
6.  Cytokines
Cytokines are small signaling molecules used for cell signaling.  The term cytokine encompasses a large and diverse family of regulators produced throughout the body by cells of diverse embryological origin.
The term cytokine has been used to refer to the immunomodulating agents, such as interleukins and interferons. Biochemists disagree as to which molecules should be termed cytokines and which hormones. As we learn more about each, anatomic and structural distinctions between the two are fading. Classic protein hormones circulate in nanomolar (10-9M) concentrations that usually vary by less than one order of magnitude. In contrast, some cytokines (such as IL-6) circulate in picomolar (10-12M) concentrations that can increase up to 1,000-fold during trauma or infection. The widespread distribution of cellular sources for cytokines may be a feature that differentiates them from hormones. Virtually all nucleated cells, but especially endo/epithelial cells and resident macrophages (many near the interface with the external environment) are potent producers of IL-1, IL-6, and TNF-a. In contrast, classic hormones, such as insulin, are secreted from discrete glands (e.g., the pancreas).  As of 2008, the current terminology refers to cytokines as immunomodulating agents. However, more research is needed in this area of defining cytokines and hormones.
Part of the difficulty with distinguishing cytokines from hormones is that some of the immunomodulating effects of cytokines are systemic rather than local. Further, as molecules, cytokines are not limited to their immunomodulatory role. For instance, cytokines are also involved in several developmental processes during embyrogenesis.

Several inflammatory cytokines are induced by oxidant stress. The fact that cytokines themselves trigger the release of other cytokines and also lead to increased oxidant stress makes them important in chronic inflammation, as well as other immunoresponses, such as fever and acute phase proteins of the liver (IL-1,6,12, INF-a).
  
Practical Steps to reduce neuroinflammation
Neuroscience is both complex and an evolving science; much remains unknown and so often there cannot be definite answers; rather judgements based on the balance of probabilities.
What is clear is that in autism we have oxidative stress and inflammation.  There also appears to be a vicious circle where the inflammation messenger itself makes that inflammation worse.  In some cases, it is the oxidative stress that triggers the inflammation; in other cases the inflammation may have other causes.
A more complex explanation relates to where the signal to the microglia came from in the first place.  Mast cells from the immune system are proposed to be the source of this signal.
For the time being let us focus on the simpler solution; that the anti-oxidant should also be the anti-inflammatory agent.  Surprise, surprise, our friend NAC is being used in numerous studies as the anti-inflammatory agent.
This is good news for Monty; it may be that NAC is not just reducing his state of oxidative stress, but gradually his neuroinflammation as well.  It certainly does seem to be doing him good.  As indicated in the research, the effect of NAC seems to be highly dose dependent.
But not to have all our eggs in one basket, it would be nice to have another anti-neuroinflammatory agent.  It seems there is one at hand, but we have to look to the East to find it.
 
Obovatol
The bark of the magnolia tree has been used in Korean, Chinese and Japanese medicine for more than a thousand years.  It seems that one compound in particular within magnolia, obovatol, has powerful properties to reduce neuroinflammation.
In another paper
and another
This is all experimental but it is clear that in theory at least, obovatol looks very interesting.
For a wider view of the medical properties of the magnolia family, there is an excellent paper from Korea that reviews the possible mechanisms. Therapeutic applications of compounds in the Magnolia family
 The proposed benefits are in the treatment of:- 
  • cancer
  • neuronal disease
  • inflammatory disease
  • cardiovascular disease 
The four active compounds are: 
  1. magnolol
  2. honokiol
  3. 4-O-methylhonokiol
  4. obovatol 
Also, anxiolytic-like effects of obovatol appeared to be mediated by the GABA benzodiazepine receptor Cl− channel opening and obovatol potentiated pentobarbital-induced sleeping time through GABA receptors/Cl− channel activation.

This data suggest that components of Magnolia could be used for treating anxiety, and its effect may be linked to GABA receptor/Cl− channel activation. 
Anti-inflammatory mechanisms of Magnolia have been reported to be associated with the suppression of NO production, the expression of iNOS, IL-1β, TNF-α and COX, the generation of prostaglandins, thromboxanes and leukotrienes, and the activation of MAPKs, AP-1 and NF-κB.
 
Magnolia Bark Extract
Magnolia bark extract is extensively produced in China and sold inexpensively by the supplement industry.  The individual compounds could be separated, as in the Korean research, but the extract that is sold is just a mixture of what happened to be in that batch of bark.  If you read the reviews, it seems that many people experience a reduction in cortisol allowing them to sleep better; reduced anxiety is widely reported.  It even seems to stop some people snoring, which I am certainly all in favour of.
So while it is far from the scientific basis on which you could use NAC, it would seem that Magnolia bark extract will unlikely do harm and just might do some good as an anti-neuroinflammatory agent.  In about 20 years, the research will show whether you were wasting your money, or whether you were a pioneering early-adopter.
I think I will do some primary research on this one and be a pioneer.